Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
- PMID: 12720218
- DOI: 10.1053/bbmt.2003.50009
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
Abstract
Reduced-intensity conditioning regimens allow application of allogeneic stem cell transplantation to greater numbers of patients with myeloma by reducing transplantation-related mortality. We prospectively evaluated the role of an approach incorporating in vivo T-cell depletion and subsequent adjuvant donor lymphocyte infusions (DLIs) as part of front-line therapy for chemotherapy-sensitive multiple myeloma. Twenty patients with HLA-matched related (n = 12) or unrelated (n = 8) donors entered the study. None had previously undergone autologous transplantation. Acute graft-versus-host disease (GVHD) following transplantation was minimal (3 grade II and no grade III or IV). Nonrelapse mortality rate was relatively low (15%) compared with conventional myeloablative allogeneic transplantation series, although it remained significantly higher than in the autologous setting. Disease responses by 6 months posttransplantation were modest (2 in complete remission, 4 in partial remission, 2 were minimally responsive, 6 had no change, 3 had progressive disease, and 3 were not evaluable). Fourteen patients received escalating-dose DLI for residual/progressive disease. Three developed acute GVHD and 2 developed limited chronic GVHD. Seven demonstrated further disease responses, which appeared to be more common in those developing GVHD (5 of 5 versus 2 of 9; P =.02). All responses were associated with conversion from mixed to full donor T-cell chimerism. Response durations were disappointing (5 <12 months) and progression often occurred despite persisting full donor chimerism. Two-year estimated overall survival and current progression-free survival rates (intention to treat with DLI from 6 months) were 71% and 30%, respectively. The current approach incorporating T-cell depletion appears excessively immunosuppressive despite attempts to restore immune function with DLI. Dose escalation failed to allow convincing dissociation of graft-versus-myeloma from GVHD. Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations.
Copyright 2003 American Society for Blood and Marrow Transplantation
Similar articles
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.Biol Blood Marrow Transplant. 2003 Mar;9(3):162-9. doi: 10.1053/bbmt.2003.50008. Biol Blood Marrow Transplant. 2003. PMID: 12652466 Clinical Trial.
-
Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.Biol Blood Marrow Transplant. 2010 Mar;16(3):320-32. doi: 10.1016/j.bbmt.2009.10.006. Epub 2009 Oct 14. Biol Blood Marrow Transplant. 2010. PMID: 19835972 Clinical Trial.
-
Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.Biol Blood Marrow Transplant. 2001;7(11):604-12. doi: 10.1053/bbmt.2001.v7.pm11760148. Biol Blood Marrow Transplant. 2001. PMID: 11760148
-
Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.Int Immunopharmacol. 2003 Aug;3(8):1121-43. doi: 10.1016/S1567-5769(03)00014-6. Int Immunopharmacol. 2003. PMID: 12860168 Review.
Cited by
-
Evolving role of high dose stem cell therapy in multiple myeloma.Indian J Med Paediatr Oncol. 2011 Jan;32(1):17-24. doi: 10.4103/0971-5851.81885. Indian J Med Paediatr Oncol. 2011. PMID: 21731211 Free PMC article.
-
Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?Best Pract Res Clin Haematol. 2007 Dec;20(4):783-95. doi: 10.1016/j.beha.2007.09.007. Best Pract Res Clin Haematol. 2007. PMID: 18070719 Free PMC article. Review.
-
Role of allogeneic transplantation in multiple myeloma in the era of new drugs.Mediterr J Hematol Infect Dis. 2010 Jun 1;2(2):e2010013. doi: 10.4084/MJHID.2010.013. Mediterr J Hematol Infect Dis. 2010. PMID: 21415966 Free PMC article.
-
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.Biol Blood Marrow Transplant. 2010 Aug;16(8):1037-69. doi: 10.1016/j.bbmt.2010.05.005. Epub 2010 May 24. Biol Blood Marrow Transplant. 2010. PMID: 20580849 Free PMC article. Review.
-
Role of allogeneic stem cell transplantation in multiple myeloma.Curr Hematol Malig Rep. 2008 Apr;3(2):99-106. doi: 10.1007/s11899-008-0015-9. Curr Hematol Malig Rep. 2008. PMID: 20425453
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials